Novartis signs gene therapy deal with Voyager for $100 mln upfront
02/01/2024 12:14
Jan 2 (Reuters) - Voyager Therapeutics VYGR.O said on Tuesday Novartis NOVN.S would pay it $100 million upfront in cash as part of a licensing deal to develop gene therapy candidates. (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar) ((Pratik.Jain@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview